KEGG   DRUG: PomalidomideHelp
Entry
D08976                      Drug                                   

Name
Pomalidomide (JAN/USAN/INN);
Pomalyst (TN)
Product
Formula
C13H11N3O4
Exact mass
273.075
Mol weight
273.2441
Structure
Mol fileKCF fileDB search
Simcomp SIMCOMP
Class
Metabolizing enzyme substrate
 DG01892  CYP1A2 substrate
 DG02913  CYP3A4 substrate
Remark
Therapeutic category: 4291
ATC code: L04AX06
Product: D08976<JP/US>
Efficacy
Antineoplastic, Immunomodulator
  Disease
Multiple myeloma [DS:H00010]
Comment
Thalidomide [DR:D00754] analog
Target
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
IL6 [HSA:3569] [KO:K05405]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04210  Apoptosis
hsa04640  Hematopoietic cell lineage
hsa04650  Natural killer cell mediated cytotoxicity
hsa04660  T cell receptor signaling pathway
hsa04668  TNF signaling pathway
Metabolism
Enzyme: CYP1A2 [HSA:1544], CYP3A4 [HSA:1576]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AX Other immunosuppressants
     L04AX06 Pomalidomide
      D08976  Pomalidomide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antiangiogenic Agents
   Pomalidomide
    D08976  Pomalidomide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D08976  Pomalidomide (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL6
     D08976  Pomalidomide (JAN/USAN/INN) <JP/US>
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D08976  Pomalidomide (JAN/USAN/INN) <JP/US>
Antineoplastics [br08340.html]
 D08976
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D08976
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08976
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D08976
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D08976
BRITE hierarchy
Other DBs
CAS: 19171-19-8
PubChem: 96025659
ChEBI: 72690
ChEMBL: CHEMBL43452
LigandBox: D08976
LinkDB All DBs
KCF data Show

ATOM        20
            1   N1y N    26.1800  -16.0300
            2   C1y C    27.5800  -16.0300
            3   C5x C    25.3400  -17.1500
            4   C5x C    25.3400  -14.9100
            5   C5x C    28.2800  -14.7700
            6   C1x C    28.2800  -17.2200
            7   C8y C    24.0100  -16.7300
            8   O5x O    25.8300  -18.4800
            9   C8y C    24.0100  -15.3300
            10  O5x O    25.7600  -13.5800
            11  N1x N    29.6800  -14.7700
            12  O5x O    27.5800  -13.5800
            13  C1x C    29.7500  -17.2200
            14  C8x C    22.8200  -17.4300
            15  C8y C    22.8200  -14.6300
            16  C5x C    30.3800  -15.9600
            17  C8x C    21.6300  -16.7300
            18  C8x C    21.6300  -15.3300
            19  O5x O    31.7800  -15.9600
            20  N1a N    22.8200  -13.2300
BOND        22
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     2   6 1
            6     3   7 1
            7     3   8 2
            8     4   9 1
            9     4  10 2
            10    5  11 1
            11    5  12 2
            12    6  13 1
            13    7  14 1
            14    9  15 1
            15   11  16 1
            16   14  17 2
            17   15  18 2
            18   16  19 2
            19    7   9 2
            20   13  16 1
            21   17  18 1
            22   15  20 1

» Japanese version   » Back

DBGET integrated database retrieval system